BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
BioXcel Therapeutics, a clinical-stage biopharmaceutical company focused on drug development utilizing artificial intelligence (AI) solutions, has recently announced its plans to initiate the SERENITY At-Home pivotal Phase 3 safety trial with a 120 mcg dose of BXCL501. This exciting move comes after a constructive meeting between BioXcel Therapeutics and the U.S. Food and Drug Administration (FDA). The initiation of this trial aims to expand the market potential of BXCL501, an investigational, proprietary sublingual thin film formulation of dexmedetomidine.
BXCL501 has demonstrated promising results in previous trials, showcasing its potential as a treatment option for various neuropsychiatric disorders and conditions. This novel therapy utilizes the unique properties of dexmedetomidine, a selective alpha-2a receptor agonist, to address acute and chronic neurological conditions.
The SERENITY At-Home trial will be an essential step towards making BXCL501 more accessible to patients, as it aims to evaluate the safety and efficacy of the treatment in the comfort of patients’ homes. By allowing patients to administer the drug themselves, this trial seeks to gather valuable real-world data on the use of BXCL501 outside of a clinical setting.
The recent meeting with the FDA has paved the way for BioXcel Therapeutics to proceed with the SERENITY At-Home trial using a 120 mcg dose of BXCL501. This dose was selected based on promising results from previous clinical trials, which demonstrated its effectiveness in treating acute agitation associated with schizophrenia and bipolar disorder.
Additionally, BioXcel Therapeutics has also made significant progress in its investigator-sponsored Phase 2 trial, studying the combination of BXCL701 with KEYTRUDA in relapsed pancreatic cancer patients. Patient enrollment in the safety portion of this trial has recently been completed, setting the stage for the human proof-of-concept portion, expected to commence in the first half of 2024. This groundbreaking trial is being led by the prestigious Georgetown Lombardi Comprehensive Cancer Center.
BXCL701 is an orally available small molecule immune-oncology agent that targets the system immune response to fight cancer. The combination of BXCL701 with KEYTRUDA, an anti-PD-1 monoclonal antibody, holds immense potential in improving outcomes for patients with relapsed pancreatic cancer.
BioXcel Therapeutics’ commitment to advancing its pipeline of innovative therapies through strategic partnerships and rigorous clinical trials showcases its dedication to improving patient care. The company’s utilization of AI solutions in drug development highlights its innovative approach, enabling the identification of novel treatment options with significant market potential.
As the SERENITY At-Home pivotal Phase 3 safety trial and the investigator-sponsored Phase 2 trial progress, BioXcel Therapeutics continues to push the boundaries of medical research and patient care. These initiatives hold great promise in expanding the treatment options available for neuropsychiatric disorders and relapsed pancreatic cancer.
Exciting
Comments